{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1390001205227076608.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1536/ihj.51.24"}},{"identifier":{"@type":"COI","@value":"1:STN:280:DC%2BC3c7gt1ekuw%3D%3D"}},{"identifier":{"@type":"PMID","@value":"20145347"}},{"identifier":{"@type":"URI","@value":"http://www.jstage.jst.go.jp/article/ihj/51/1/51_1_24/_pdf"}},{"identifier":{"@type":"NAID","@value":"130000162391"}},{"identifier":{"@type":"URI","@value":"https://search.jamas.or.jp/link/ui/2010180289"}}],"resourceType":"学術雑誌論文(journal article)","dc:title":[{"@language":"en","@value":"Relationship Between CHADS2 Score and Ischemic Stroke During Rhythm Control Therapy for Paroxysmal Atrial Fibrillation"}],"dc:language":"en","description":[{"type":"abstract","notation":[{"@language":"en","@value":"The CHADS<sub>2</sub> score has been proposed for stratifying patients with nonvalvular atrial fibrillation (NVAF) according to the risk of thromboembolism in the AHA/ACC/ESC guidelines. However, there is little information about its usefulness for predicting the long-term risk of ischemic stroke in Japanese patients with paroxysmal AF. We retrospectively evaluated the incidence of ischemic stroke and the efficacy of anticoagulant therapy in paroxysmal AF patients on rhythm control therapy who were stratified by their CHADS<sub>2</sub> score. The subjects were 334 NVAF patients (229 men and 105 women, mean age, 68 ± 12 years, mean follow-up period, 60 ± 35 months) who were categorized into low risk (score 0), moderate risk (1 or 2), and high risk (3 or more) groups for thromboembolism.<br>The low, moderate, and high risk groups accounted for 34%, 50%, and 16% of the patients, respectively. Among 257 patients without warfarin therapy, the annual rate of symptomatic ischemic stroke was 0.6% in the score 0 group, 0.5% in the score 1 group, 3.1% in the score 2 group, and 9.6% in the score 3 or more group. Among 77 patients treated with warfarin (target PT-INR: 1.6-3.0), the stroke rate was 0% in the score 0 group, 0% in the score 1 group, 1.4% in the score 2 group, and 6.6% in the score 3 or more group. The annual rate of ischemic stroke was 0.88% in patients treated with warfarin versus 2.67% in those without warfarin, or a decrease in risk of 68% with warfarin (<i>P</i> < 0.01). In Japanese patients with paroxysmal AF, the CHADS<sub>2</sub> score is useful for predicting the risk of ischemic stroke. Anticoagulant therapy is needed to prevent ischemic stroke in patients with paroxysmal AF, especially those who have a CHADS<sub>2</sub> score of 2 or more."}],"abstractLicenseFlag":"disallow"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1410001205227076614","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000021603178"}],"foaf:name":[{"@language":"en","@value":"Komatsu Takashi"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Division of Cardiology, Department of Internal Medicine, Iwate Medical University School of Medicine"}]},{"@id":"https://cir.nii.ac.jp/crid/1410001205227076612","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000021603181"}],"foaf:name":[{"@language":"en","@value":"Tachibana Hideaki"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Division of Cardiology, Department of Internal Medicine, Iwate Medical University School of Medicine"}]},{"@id":"https://cir.nii.ac.jp/crid/1410001205227076613","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000021603184"}],"foaf:name":[{"@language":"en","@value":"Sato Yoshihiro"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Division of Cardiology, Department of Internal Medicine, Iwate Medical University School of Medicine"}]},{"@id":"https://cir.nii.ac.jp/crid/1410001205227076609","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000021603187"}],"foaf:name":[{"@language":"en","@value":"Ozawa Masato"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Division of Cardiology, Department of Internal Medicine, Iwate Medical University School of Medicine"}]},{"@id":"https://cir.nii.ac.jp/crid/1410001205227076610","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000021603189"}],"foaf:name":[{"@language":"en","@value":"Kunugida Fusanori"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Division of Cardiology, Department of Internal Medicine, Iwate Medical University School of Medicine"}]},{"@id":"https://cir.nii.ac.jp/crid/1420001326235106048","@type":"Researcher","personIdentifier":[{"@type":"KAKEN_RESEARCHERS","@value":"70508986"},{"@type":"NRID","@value":"1000070508986"},{"@type":"NRID","@value":"9000283595221"},{"@type":"NRID","@value":"9000403417659"},{"@type":"NRID","@value":"9000307263829"},{"@type":"NRID","@value":"9000243882268"},{"@type":"NRID","@value":"9000018706512"},{"@type":"NRID","@value":"9000242071636"},{"@type":"NRID","@value":"9000014672818"},{"@type":"NRID","@value":"9000297495467"},{"@type":"NRID","@value":"9000410299150"},{"@type":"NRID","@value":"9000021941318"},{"@type":"NRID","@value":"9000261041548"},{"@type":"NRID","@value":"9000021241780"},{"@type":"NRID","@value":"9000014675863"},{"@type":"NRID","@value":"9000021603191"},{"@type":"NRID","@value":"9000290821371"},{"@type":"NRID","@value":"9000283561693"},{"@type":"NRID","@value":"9000272989869"},{"@type":"NRID","@value":"9000415349061"},{"@type":"NRID","@value":"9000006863524"},{"@type":"NRID","@value":"9000342800282"},{"@type":"NRID","@value":"9000006747398"},{"@type":"NRID","@value":"9000283559773"},{"@type":"NRID","@value":"9000296663700"},{"@type":"NRID","@value":"9000259833575"},{"@type":"NRID","@value":"9000256884773"},{"@type":"NRID","@value":"9000257831335"},{"@type":"NRID","@value":"9000240051652"},{"@type":"RESEARCHMAP","@value":"https://researchmap.jp/kori931"}],"foaf:name":[{"@language":"en","@value":"Orii Makoto"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Division of Cardiology, Department of Internal Medicine, Iwate Medical University School of Medicine"}]},{"@id":"https://cir.nii.ac.jp/crid/1410001205227076608","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000021603193"}],"foaf:name":[{"@language":"en","@value":"Nakamura Motoyuki"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Division of Cardiology, Department of Internal Medicine, Iwate Medical University School of Medicine"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"13492365"},{"@type":"LISSN","@value":"13492365"},{"@type":"EISSN","@value":"13493299"}],"prism:publicationName":[{"@language":"en","@value":"International Heart Journal"},{"@language":"en","@value":"Int. Heart J."}],"dc:publisher":[{"@language":"en","@value":"International Heart Journal Association"},{"@language":"ja","@value":"一般社団法人 インターナショナル・ハート・ジャーナル刊行会"}],"prism:publicationDate":"2010","prism:volume":"51","prism:number":"1","prism:startingPage":"24","prism:endingPage":"29"},"reviewed":"false","dcterms:accessRights":"http://purl.org/coar/access_right/c_abf2","url":[{"@id":"http://www.jstage.jst.go.jp/article/ihj/51/1/51_1_24/_pdf"},{"@id":"https://search.jamas.or.jp/link/ui/2010180289"}],"availableAt":"2010","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=Paroxysmal%20atrial%20fibrillation","dc:title":"Paroxysmal atrial fibrillation"},{"@id":"https://cir.nii.ac.jp/all?q=Thromboembolism","dc:title":"Thromboembolism"},{"@id":"https://cir.nii.ac.jp/all?q=Anticoagulant%20therapy","dc:title":"Anticoagulant therapy"},{"@id":"https://cir.nii.ac.jp/all?q=Antiarrhythmic%20therapy","dc:title":"Antiarrhythmic therapy"},{"@id":"https://cir.nii.ac.jp/all?q=CHADS%3Csub%3E2%3C/sub%3E%20score","dc:title":"CHADS<sub>2</sub> score"}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360011144181850368","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Accumulation of risk factors enhances the prothrombotic state in atrial fibrillation"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011144724587392","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292621390993152","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"A Comparison of Rate Control and Rhythm Control in Patients with Atrial Fibrillation"}]},{"@id":"https://cir.nii.ac.jp/crid/1360306905176423040","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Clinical impact of cardiovascular calcifications on stroke incidence in primary prevention: analysis in NADESICO study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574096124755456","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Factors Associated With Ischemic Stroke During Aspirin Therapy in Atrial Fibrillation"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574096410196992","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Stroke Prevention in Atrial Fibrillation Study. Final results."}]},{"@id":"https://cir.nii.ac.jp/crid/1361418519354036864","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Stroke Reduction in Hypertensive Adults With Cardiac Hypertrophy Randomized to Losartan Versus Atenolol"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418519614727168","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Atrial fibrillation: Maintenance of sinus rhythm versus rate control"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981468349043584","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Prevalence of atrial fibrillation in the general population of Japan: An analysis based on periodic health examination"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544419057652992","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Atrial Fibrillation and Thromboembolism: A Decade of Progress in Stroke Prevention"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544419058224640","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"PLACEBO-CONTROLLED, RANDOMISED TRIAL OF WARFARIN AND ASPIRIN FOR PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN CHRONIC ATRIAL FIBRILLATION"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825894446477184","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Epidemiology and natural history of atrial fibrillation: clinical implications"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825895416990464","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Validation of Clinical Classification Schemes for Predicting Stroke"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825896097319296","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Monitored Atrial Fibrillation Duration Predicts Arterial Embolic Events in Patients Suffering From Bradycardia and Atrial Fibrillation Implanted With Antitachycardia Pacemakers"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825896317255552","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Patients With Nonvalvular Atrial Fibrillation at Low Risk of Stroke During Treatment With Aspirin: Stroke Prevention in Atrial Fibrillation III Study"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107369153199872","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Low-Dose Aspirin for Prevention of Stroke in Low-Risk Patients With Atrial Fibrillation"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107370148722688","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Cardiogenic Brain Embolism"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107371204432384","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"A Comparison of Rate Control and Rhythm Control in Patients with Recurrent Persistent Atrial Fibrillation"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670320366226560","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"The Effect of Low-Dose Warfarin on the Risk of Stroke in Patients with Nonrheumatic Atrial Fibrillation"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670320469522048","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Atrial Fibrillation: A Major Contributor to Stroke in the Elderly"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670321311820160","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951793692243072","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Canadian atrial fibrillation anticoaguiation (CAFA) study"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951794324471424","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233270713445632","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"A Clinical Prediction Rule to Identify Patients With Atrial Fibrillation and a Low Risk for Stroke While Taking Aspirin"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233270891811456","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Contrast sonography for detection of vesicoureteral reflux"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204771839872","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"3．本邦における非弁膜症性発作性心房細動例の虚血性脳卒中および全身性塞栓症のリスク層別化―CHADS<SUB>2</SUB>ならびにCHA<SUB>2</SUB>DS<SUB>2</SUB>-VAScスコアとの比較―"},{"@language":"en","@value":"Comparison between CHADS2 and CHA2DS2 -VASc Score for the Risk Stratification of Ischemic Stroke in Japanese Patients with Nonvalvular Paroxysmal Atrial Fibrillation"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001205104593664","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Long-Term Prognosis of Patients With Paroxysmal Atrial Fibrillation Depends on Their Response to Antiarrhythmic Therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001205224957952","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Comparison Between CHADS<sub>2</sub> and CHA<sub>2</sub>DS<sub>2</sub>-VASc Score for Risk Stratification of Ischemic Stroke in Japanese Patients With Non-Valvular Paroxysmal Atrial Fibrillation Not Receiving Anticoagulant Therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001206432452352","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Prevalence and Clinical Characteristics of Patients With Atrial Fibrillation"},{"@value":"Prevalence and clinical characteristics of patients with atrial fibrillation: analysis of 20,000 cases in Japan"},{"@value":"Hokkaido Atrial Fibrillation Study Group. Prevalence and clinical characteristics of patients with atrial fibrillation: analysis of 20,000 cases in Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282680080114816","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Recent Mortality and Morbidity Rates of Japanese Atrial Fibrillation Patients"},{"@value":"Recent mortality and morbidity rates of Japanese atrial fibrillation patients: racial differences and risk stratification"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282680080894208","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Investigation of the Optimal Treatment Strategy for Atrial Fibrillation in Japan-The J-RHYTHM (Japanese Rhythm Management Trial for Atrial Fibrillation) Study Design-"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282680202408704","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Combination Therapy With Amiodarone and Enalapril in Patients With Paroxysmal Atrial Fibrillation Prevents the Development of Structural Atrial Remodeling"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282680203723904","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Incidence, Predictors and Impact of Severe Periprocedural Bleeding According to VARC-2 Criteria on 1-Year Clinical Outcomes in Patients After Transcatheter Aortic Valve Implantation"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282680221860224","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Efficacy of Long-term Flecainide Therapy in Patients with Paroxysmal Atrial Fibrillation-Analysis Based on Time of Onset-"},{"@value":"Efficacy of Long‐term Flecainide Therapy in Patients with Paroxysmal Atrial Fibrillation —Analysis Based on Time of Onset—"}]},{"@id":"https://cir.nii.ac.jp/crid/1570572701188845184","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Relationship between CHA_2DS_2-VASc scores and ischemic stroke/cardiovascular events in Japanese patients with paroxysmal atrial fibrillation without receiving anticoagulat therapy"}]}],"dataSourceIdentifier":[{"@type":"JALC","@value":"oai:japanlinkcenter.org:0034700229"},{"@type":"CROSSREF","@value":"10.1536/ihj.51.24"},{"@type":"PUBMED","@value":"20145347"},{"@type":"CIA","@value":"130000162391"},{"@type":"OPENAIRE","@value":"doi_dedup___::29608b8dfc004411b71fcd949a5f3c89"},{"@type":"CROSSREF","@value":"10.1007/s00380-024-02394-6_references_DOI_aI0hzAzApg3SBM4yefVlNF65AFp"},{"@type":"CROSSREF","@value":"10.1536/ihj.15-195_references_DOI_aI0hzAzApg3SBM4yefVlNF65AFp"},{"@type":"CROSSREF","@value":"10.1536/ihj.13-242_references_DOI_aI0hzAzApg3SBM4yefVlNF65AFp"},{"@type":"CROSSREF","@value":"10.5105/jse.33.40_references_DOI_aI0hzAzApg3SBM4yefVlNF65AFp"}]}